406687-57-8

Basic information

• Product Name: 2-Propynal, 3-(2-fluorophenyl)- (9CI)
• Synonyms: 2-Propynal, 3-(2-fluorophenyl)- (9CI)
• CAS NO: 406687-57-8
• Molecular Formula: C₉H₅FO
• Molecular Weight: 148.1338032
• Product Categories: HALIDE
• Mol File: 406687-57-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Propynal, 3-(2-fluorophenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propynal, 3-(2-fluorophenyl)- (9CI)(406687-57-8)
• EPA Substance Registry System: 2-Propynal, 3-(2-fluorophenyl)- (9CI)(406687-57-8)

Safety Data

• Hazardous Substances Data: 406687-57-8(Hazardous Substances Data)

Upstream product

• 766-49-4 (2-fluorophenyl)acetylene 
• 68-12-2 N,N-dimethyl-formamide 
• 348-52-7 1-Fluoro-2-iodobenzene 
• 208183-93-1 3-(2-fluorophenyl)-prop-2-yn-1-ol 

Downstream Products

• 1322081-08-2 ethyl (R)-4-(2-fluorophenyl)-6-methyl-2-oxo-3,4-dihydro-2H-pyran-5-carboxylate 
• 1620556-63-9 methyl 2-fluoro-3-(2-fluorophenyl)-3-oxopropanoate 

Relevant articles and documents

NHC-catalyzed enantioselective C2-functionalization of 3-hydroxychromenonesviaα,β-unsaturated acyl azoliums

A novel synthetic method for enantioselective C2-functionalization of 3-hydroxychromenones promoted by N-heterocyclic carbenesviathe formation of α,β-unsaturated acyl azolium intermediates, which occurs with Coates-Claisen rearrangement is established. This synthetic strategy enabled the rapid assembly of enantiomerically enriched δ-hydroxychromenone-derived esters/amides under mild conditions with good to excellent yields and broad substrate scope.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Applications of Thermal Activation, Ball-milling and Aqueous Medium in Stereoselective Michael Addition of Nitromethane to Enynones Catalyzed by Chiral Squaramides

Stereoselective addition of nitromethane to conjugated en-ynones was performed through the application of chiral squaramides. Three non-classical approaches to promote the addition reaction were tested, including activation of the nucleophile by inorganic base in a biphasic aqueous system, thermal activation, and ball-milling. Hydrogen-bonding catalysis was effective in all these methods, providing 1,4-addition products in high yields and stereoselectivities of up to 98% requiring 1–5 mol% of Cinchona alkaloid squaramide. (Figure presented.).

Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists

Novel series of compounds consisting of 2-amidocyclohex-1-ene carboxylate and phenyl parts which are connected by enyne (compounds 2a–f), but-1-yne (compounds 4a–j), and phenylethylene (compounds 5a–f) linkers as HCA2 full agonists were designed and their